Minimalized Plasmids with Conditional Replication Origins
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current plasmid therapies and vaccines face regulatory safety concerns due to promiscuous replication in endogenous bacterial flora and the presence of antibiotic resistance markers, and they often have low antigen expression levels, limiting their effectiveness in gene therapy and immunization applications.
Innovation Solution
Development of minimalized eukaryotic expression plasmids with novel replication origins such as R6K gamma and ColE2-P9, which are replication incompetent in endogenous flora and utilize RNA selectable markers instead of antibiotic resistance markers, combined with heat-inducible replication protein expression systems to enhance antigen expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If pMB1, ColE1 or pBR322 derived replication origin is used, then plasmid replication is efficient in E. coli, but plasmid transfer and replication in endogenous bacterial flora occurs causing safety concerns
Solution Approach 1:
The patent extracts and removes the problematic pMB1, ColE1, or pBR322 replication origins from the plasmid vector, replacing them with conditional replication origins that are restricted to specific host cells. This extraction eliminates the harmful promiscuous replication capability while preserving essential plasmid functions.
Solution Approach 2:
The patent changes the replication parameter by using conditional replication origins (such as temperature-sensitive or host-range restricted origins) instead of constitutive ones. This parameter change allows replication only under specific conditions or in specific host cells, preventing unauthorized replication in endogenous flora.
2Reliability
If antibiotic resistance markers are used for selection, then plasmid maintenance is ensured, but expression of selection markers in human cells or endogenous flora creates safety concerns
Solution Approach 1:
The patent extracts and removes antibiotic resistance markers and other non-essential selection markers from the plasmid vector. This extraction eliminates the risk of marker expression in human cells or endogenous flora while maintaining plasmid functionality through alternative means.
Solution Approach 2:
The patent employs transient or conditional selection strategies that do not require permanent marker expression. Selection is achieved through temporary mechanisms that are inactive or non-functional in the final application context, eliminating long-term safety concerns.
3Object-affected harmful factors
If plasmid vectors are minimized to eliminate non-essential sequences, then safety is improved, but antigen expression levels decrease
Solution Approach 1:
The patent changes key parameters of the minimal plasmid vector, including using enhanced promoter elements, optimizing coding sequences for expression, and incorporating stabilizing sequences. These parameter optimizations maintain safety through minimization while compensating for expression losses through targeted enhancements.
Solution Approach 2:
The patent creates a composite plasmid structure that combines minimal safety-focused elements with optimized expression components. The vector integrates essential minimal sequences for safety with enhanced regulatory elements and coding optimizations to achieve both safety and high expression levels.
4Reliability
If all non-essential sequences are removed to create minimalized plasmids, then regulatory safety requirements are met, but production yield and expression efficiency are reduced
Solution Approach 1:
The patent optimizes parameters of the minimal plasmid including copy number control, promoter strength, and sequence composition to maximize production yield within the constraints of regulatory compliance. Careful parameter tuning allows high expression from minimal vectors.
Solution Approach 2:
The patent introduces dynamic control elements to the minimal plasmid, such as inducible promoters or conditional replication origins, that allow the system to adapt expression levels and replication activity based on growth phase or environmental conditions, thereby optimizing production yield from a minimal vector framework.
Data Source
AI summary
The present invention relates to the production and use of covalently closed circular (ccc) recombinant plasmids, and more particularly to vector modifications that improve expression of said DNA molecules in the target organism.